Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | USP19 | O94966 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884467 | 0.91 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAALDH1A1HPGDMAPK1 | |
| SCHEMBL886633 | 0.89 | HDAC1 (0.34) | BRD4HDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL885526 | 0.87 | SMN1; SMN2 (0.34) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA | |
| SCHEMBL885529 | 0.86 | ALDH1A1 (0.35) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA | |
| SCHEMBL885599 | 0.86 | HDAC1 (0.33) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA | |
| SCHEMBL884554 | 0.85 | TDP1 (0.34) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA | |
| SCHEMBL885536 | 0.85 | PDE10A (0.34) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA | |
| SCHEMBL885584 | 0.85 | HDAC1 (0.32) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA | |
| SCHEMBL886180 | 0.85 | HDAC1 (0.33) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA | |
| SCHEMBL2062369 | 0.84 | SMN1; SMN2 (0.34) | HDAC1HDAC8HDAC6SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | claimed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | claimed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | claimed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | ENPP2 2133/4885BRD4 3102/4885HDAC1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.